Navigating Corneal Adverse Events Associated with Antibody Drug Conjugates in Oncology

As the number of cancer patients receiving targeted treatments grows, optometrists will see more referrals from oncologists to manage ocular side effects. Eye care professionals must be aware of, assess, and manage potential side effects to ensure timely care for patients with eye-related issues. There are challenges with ocular adverse events, as no 'antidote' exists—only dose holds, which can cause anxiety for less experienced providers. By the end of this program, you’ll be equipped to identify and manage corneal toxicities from ADCs, ensuring optimal care for oncology patients and improving multidisciplinary collaborative care skills.

Proposed learning objectives:

1. Understand cancer therapies and the ocular toxicities associated with antibody drug conjugates (ADCs).
2. Identify and manage ocular adverse events related to ADCs through collaborative decision-making and patient case discussions.
3. Clarify the roles of eye care professionals and oncologists in managing ocular toxicities and fostering effective interdisciplinary collaboration.

Breakfast provided and sponsored by: GSK